Dr Lalchand. Lab

Why is Dr Lalchandani Labs Ltd falling/rising?

As of 09-Jul, Dr Lalchandani Labs Ltd's stock price is at 8.22, unchanged from the previous session. Despite a year-to-date decline of 60.50%, recent short-term performance shows a 3.66% increase and heightened investor interest, indicating potential for recovery.

As of 09-Jul, Dr Lalchandani Labs Ltd's stock price is currently at 8.22, showing no change from the previous trading session. The stock has experienced a mixed performance over various periods. In the past week, it has risen by 3.66%, outperforming the Sensex, which fell by 0.98%. However, over the longer term, the stock has faced significant declines, with a year-to-date drop of 60.50% and a one-year decline of 60.06%. <BR><BR>Despite these long-term challenges, there are indications of positive momentum in the short term. The stock's performance today has outperformed its sector by 3.22%, and there has been a notable increase in investor participation, with delivery volume rising by 129.17% compared to the five-day average. This suggests that while the stock has struggled overall, recent trading activity indicates a potential for recovery or increased interest from investors.<BR><BR>In terms of moving averages, the stock is currently higher than its 5-day moving average but lower than its 20-day, 50-day, 100-day, and 200-day moving averages, indicating a mixed technical outlook. The liquidity of the stock is also adequate, as it is based on 2% of the five-day average traded value, suggesting it is liquid enough for trading.<BR><BR>In summary, while Dr Lalchandani Labs Ltd has faced significant declines over the longer term, recent short-term performance and increased investor participation may be contributing to a stabilization or slight rise in its stock price.

Which are the latest news on Dr Lalchand. Lab?

What does Dr Lalchand. Lab do?

Dr Lalchandani Labs Ltd provides pathology laboratory services and operates as a micro-cap company with a market cap of INR 9 Cr. It was incorporated in 2011 and transitioned to a limited company in 2017, with no recent sales or profit data reported.

Overview:<BR>Dr Lalchandani Labs Ltd operates in the healthcare services industry, focusing on pathology laboratory services and is categorized as a micro-cap company.<BR><BR>History:<BR>The company was originally incorporated as a Partnership Firm in New Delhi on 15 September 2011 under the name Dr. A Lalchandani Pathology Laboratories. It transitioned to a limited company on 2nd August 2017, following an agreement dated 31st August 2017. There is no recent sales or profit data reported.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: INR 9 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 135.00<BR>Industry P/E: 60<BR>Dividend Yield: 0.00%<BR>Debt-Equity: 0.08<BR>Return on Equity: 0.60%<BR>Price to Book: 0.81<BR><BR>Contact Details:<BR>Address: M-20 Basement, Greater Kailash-1 New Delhi, New Delhi: 110048<BR>Tel: 91-11-49057058<BR>Email: info@lalchandanipathlab.com<BR>Website: http://www.lalchandanipathlab.com

How big is Dr Lalchand. Lab?

As of 10th June, Dr Lalchandani Labs Ltd has a market capitalization of 9.00 Cr, classifying it as a Micro Cap company, with Shareholder's Funds of 9.96 Cr and Total Assets of 15.75 Cr reported as of March 2025. There is no valid financial data available for the latest four quarters.

As of 10th June, <BR><BR>Market Cap: Dr Lalchandani Labs Ltd has a market capitalization of 9.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for the latest four quarters, including Net Sales and Net Profit.<BR><BR>Balance Sheet Snapshot: The latest reporting period is March 2025, with Shareholder's Funds amounting to 9.96 Cr and Total Assets valued at 15.75 Cr.

Who are in the management team of Dr Lalchand. Lab?

The management team of Dr Lalchand Lab includes Arjan Lalchandani (Chairman & Managing Director), Mohit Lalchandani (Whole Time Director & CEO), Anchal Gupta (Executive Director & CFO), and independent directors Rajiv Handa and Prakash Jhuraney, along with director Swati Chandra.

The management team of Dr Lalchand Lab includes the following individuals:<BR><BR>1. **Arjan Lalchandani** - Chairman & Managing Director<BR>2. **Mohit Lalchandani** - Whole Time Director & CEO<BR>3. **Anchal Gupta** - Executive Director & CFO<BR>4. **Rajiv Handa** - Independent Director<BR>5. **Prakash Jhuraney** - Independent Director<BR>6. **Swati Chandra** - Director<BR><BR>If you need more details about any specific member or their roles, feel free to ask!

Who are the peers of the Dr Lalchand. Lab?

Dr. Lalchand. Lab's peers include Adeshwar Meditex, Transgene Biotek, Family Care, Vanta Bioscience, Clinitech Lab, Looks Health, Dhanvantri Jeev., Ashram Online, and Gian Lifecare. The lab has a good capital structure but a below-average management risk and growth compared to its peers.

Peers: The peers of Dr Lalchand. Lab are Adeshwar Meditex, Transgene Biotek, Family Care, Vanta Bioscience, Clinitech Lab, Looks Health, Dhanvantri Jeev., Ashram Online, and Gian Lifecare.<BR><BR>Quality Snapshot: Below Average management risk is observed at Adeshwar Meditex, Vanta Bioscience, Clinitech Lab, Dr Lalchand. Lab, Dhanvantri Jeev., and Gian Lifecare, while Average management risk is found at Family Care. Transgene Biotek, Looks Health, and Ashram Online do not qualify for management risk assessment. Good growth is noted at Family Care, while Below Average growth is seen at Adeshwar Meditex, Vanta Bioscience, Clinitech Lab, Dr Lalchand. Lab, Dhanvantri Jeev., and Gian Lifecare, with Transgene Biotek, Looks Health, and Ashram Online not qualifying. Excellent capital structure is present at Family Care, while Good capital structure is found at Dr Lalchand. Lab, Dhanvantri Jeev., and Gian Lifecare, with Average capital structure at Adeshwar Meditex, and Below Average at Vanta Bioscience and Clinitech Lab; Transgene Biotek, Looks Health, and Ashram Online do not qualify.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Looks Health at 96.39%, while Gian Lifecare has the lowest at -62.42%. Dr Lalchand. Lab's 1-year return is -40.03%, which is better than Gian Lifecare's but worse than Looks Health's. Additionally, the six-month return is negative for Adeshwar Meditex, Vanta Bioscience, Dr Lalchand. Lab, Dhanvantri Jeev., Ashram Online, and Gian Lifecare.

Is Dr Lalchand. Lab overvalued or undervalued?

As of December 4, 2025, Dr Lalchand Lab's valuation has improved to attractive, indicating it is undervalued with a PE ratio of 19.83, an EV to EBITDA of 8.75, and a Price to Book Value of 0.84, making it more affordable compared to peers like Max Healthcare and Apollo Hospitals, while also outperforming the Sensex with a year-to-date return of 13.73%.

As of 4 December 2025, the valuation grade for Dr Lalchand. Lab has moved from risky to attractive, indicating a significant improvement in its investment appeal. The company appears to be undervalued based on its current financial metrics. Notable ratios include a PE ratio of 19.83, an EV to EBITDA of 8.75, and a Price to Book Value of 0.84, which suggest that the stock is trading at a discount relative to its earnings and assets.<BR><BR>When compared to peers, Dr Lalchand. Lab's valuation stands out positively. For instance, Max Healthcare is classified as very expensive with a PE ratio of 74.46, while Apollo Hospitals, also attractive, has a PE of 61.81. This comparison highlights Dr Lalchand. Lab's relative affordability in the healthcare services sector. Additionally, the company's recent stock performance shows a year-to-date return of 13.73%, outperforming the Sensex's 9.12%, reinforcing the notion that it may be undervalued in the current market.

How has been the historical performance of Dr Lalchand. Lab?

Dr Lalchand. Lab has experienced a decline in net sales and profitability, with total operating income dropping from 11.28 Cr in Mar'22 to 4.45 Cr in Mar'25, and profit before tax decreasing from 1.25 Cr to 0.40 Cr in the same period. Total assets and liabilities also decreased, while cash flow from operating activities remained stagnant, though a net cash inflow of 1.00 Cr was recorded in Mar'25.

Answer:<BR>The historical performance of Dr Lalchand. Lab shows a declining trend in net sales and profitability over the past few years, with a significant drop in total operating income from 11.28 Cr in Mar'22 to 4.45 Cr in Mar'25. The operating profit margin has fluctuated, peaking at 28.9% in Mar'24 before falling to 23.37% in Mar'25. Profit before tax also saw a decline, moving from 1.25 Cr in Mar'22 to 0.40 Cr in Mar'25, while profit after tax decreased from 0.93 Cr in Mar'22 to 0.42 Cr in Mar'25. The company’s total assets decreased from 18.12 Cr in Mar'22 to 15.75 Cr in Mar'25, and total liabilities also saw a reduction from 18.12 Cr to 15.75 Cr in the same period. Cash flow from operating activities has been stagnant, with no inflow reported in the last two years, although there was a net cash inflow of 1.00 Cr in Mar'25.<BR><BR>Breakdown:<BR>Dr Lalchand. Lab's financial performance has shown a notable decline in net sales, which decreased from 11.28 Cr in Mar'22 to 4.45 Cr in Mar'25. This decline is reflected in the total operating income, which also fell significantly over the years. The operating profit margin peaked at 28.9% in Mar'24 but dropped to 23.37% in Mar'25, indicating challenges in maintaining profitability. Profit before tax decreased from 1.25 Cr in Mar'22 to 0.40 Cr in Mar'25, while profit after tax followed a similar trend, moving from 0.93 Cr to 0.42 Cr. The company's total assets decreased from 18.12 Cr in Mar'22 to 15.75 Cr in Mar'25, with total liabilities also reducing in the same timeframe. Cash flow from operating activities has remained stagnant, with no inflow in recent years, although a net cash inflow of 1.00 Cr was recorded in Mar'25, suggesting some improvement in liquidity.

When is the next results date for Dr Lalchand. Lab?

Dr Lalchand. Lab will announce its results on 14 November 2025.

Dr Lalchand. Lab is scheduled to declare its results on 14 November 2025.

What is the technical trend for Dr Lalchand. Lab?

As of June 2, 2025, Dr. Lalchand Lab's trend is mildly bearish, influenced by daily moving averages and mixed signals from MACD and Bollinger Bands, with weekly indicators showing mild bullishness and monthly indicators remaining bearish.

As of 2 June 2025, the technical trend for Dr Lalchand. Lab has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, but the monthly MACD remains bearish, indicating mixed signals. The daily moving averages are mildly bearish, while the weekly Bollinger Bands are bullish, contrasting with the monthly Bollinger Bands that are mildly bearish. The KST shows a mildly bullish stance on the weekly chart but is bearish on the monthly. Dow Theory indicates no trend on the weekly and mildly bullish on the monthly. Overall, the current stance is mildly bearish, driven primarily by the daily moving averages and the mixed signals from MACD and Bollinger Bands.

Who are the top shareholders of the Dr Lalchand. Lab?

The top shareholder of Dr Lalchand Lab is Arjan Lal Chandani, with a 42.53% stake, followed by public shareholder Amit Charan at 5.08%. Individual investors own 45.68% of the company, with no institutional or pledged promoter holdings.

The top shareholders of Dr Lalchand Lab include Arjan Lal Chandani, who holds the largest stake at 42.53%. Following him, the highest public shareholder is Amit Charan, with a holding of 5.08%. Additionally, individual investors collectively own 45.68% of the company. Notably, there are no institutional holdings from mutual funds or foreign institutional investors, and there are no pledged promoter holdings.

Has Dr Lalchand. Lab declared dividend?

No Dividend History Available